MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer.
In addition, MannKind is applying our novel technologies and services to support partner development efforts. More >
Our lead investigational product candidate, AFREZZA®
MannKind has completed Phase 3 Clinical Study of AFREZZA in Patients with Type 1 Diabetes (Affinity 1) and in Patients with Type 2 Diabetes (Affinity 2).
Read the latest press release here.